Navigation Links
A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits
Date:7/14/2009

n problem is memory. However, not everyone diagnosed with MCI goes on to develop Alzheimer's. There is currently no treatment for MCI approved by the FDA. Numerous clinical trials are investigating treatments to delay or prevent Alzheimer's in MCI populations.

Scott Roberts, PhD, Assistant Professor of Health Behavior & Health Education at the University of Michigan's School of Public Health; Jason Karlawish, MD, Associate Professor of Medicine and Medical Ethics with tenure, Senior Fellow of the Center for Bioethics and the Leonard Davis Institute of Health Economics, and Associate Scholar at the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania; and colleagues sought to assess how neurologists are diagnosing and treating patients with mild cognitive symptoms and how they view MCI as a clinical diagnosis. They surveyed members of the AmericanAcademy of Neurology (AAN) who had indicated a clinical practice focus on aging/dementia or behavioral neurology in a recent AAN Member Census using mail, fax and the Internet.

420 clinicians (response rate=48%) completed the survey. 88% reported at least monthly encounters with patients experiencing mild cognitive symptoms. Most respondents recognize MCI as a clinical diagnosis (90%) and use its diagnostic code for billing purposes (70%). When seeing this population, most respondents report routinely making recommendations for monitoring and follow-up (88%), counseling patients on physical (78%) and mental exercise (75%), and communicating about risk of dementia (63%).

Most respondents (70%) prescribe cholinesterase inhibitors at least sometimes for this population, with memantine (39%) and "other" agents (e.g., vitamin E, gingko) prescribed less frequently. Cholinesterase inhibitors and memantine are FDA-approved drugs for Alzheimer's. Relatively few respondents routinely provide information on support services (27%) or a wr
'/>"/>

SOURCE Alzheimer's Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Carolina (PRWEB) December 25, 2014 ... Carolina Retirement Community, recently showed their generous spirit ... of the Catawba County Parenting Network- Grandparents Raising ... 10 children gathered around the largest Christmas tree ... open presents purchased by residents of the Abernethy ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... 2014 New studies reveal that women under ... related depression (March 6, 2014, JAMA Otolaryngology*). And although many ... (about 50 percent according to recent polls) facing hearing loss ... a person feels and relates to the world. People who ... also made by way of:, , self-confidence ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, has presented ... a site-wide wedding gown promotion. , For those ... more unexpected way, the collection should be a great choice. ... market, and they are available with custom service. , Now, ... prices, up to 75% off; most of them come in ...
Breaking Medicine News(10 mins):Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... HCA today announced financial,and operating results for the third quarter ... increased 5.7 percent to $6.569 billion. -- Adjusted EBITDA totaled ... the prior year. -- Net income totaled $300 million, ... year. -- Interest expense increased to $560 million, up from ...
... in 2008, HOUSTON, Nov. 7 In ... and RediClinic Services units of RediClinic,LLC have been ... have been promoted and two new executives have ... chief operating officer of the RediClinic,division, has been ...
... America, the premier network,of diabetes care and management centers ... its physicians have been recognized by the,Diabetes Physician Recognition ... Dr. Wendy Hawkins M.D., Dr. Damon,Weddington M.D., Dr. Alice ... M.D. were all honored in Houston today. "The ...
... Inc. (Amex:,ADL), with operations in Shenzhen, Jiangxi and ... Inc. (JPI), which is an,international biopharma company that ... pharmaceutical and diagnostic,products, announced today that JPI,s subsidiary ... agreements for its new anti-aging and skin,care injectable ...
... at 8:00 a.m. ET -, VALENCIA, Calif., Nov. ... financial results for the third quarter ended,September 30, 2007. ... expenses were $75.6,million, compared to $61.1 million for the ... was attributed to increased research,and development (R&D) expenses which ...
... Insulet Corporation,(Nasdaq: PODD ), the manufacturer and marketer ... of its public offering of,4,898,398 shares of common stock ... by selling stockholders. Insulet will not receive any proceeds,from ... has granted to,the underwriters an option to purchase up ...
Cached Medicine News:Health News:HCA Reports Third Quarter 2007 Results 2Health News:HCA Reports Third Quarter 2007 Results 3Health News:HCA Reports Third Quarter 2007 Results 4Health News:HCA Reports Third Quarter 2007 Results 5Health News:HCA Reports Third Quarter 2007 Results 6Health News:HCA Reports Third Quarter 2007 Results 7Health News:HCA Reports Third Quarter 2007 Results 8Health News:HCA Reports Third Quarter 2007 Results 9Health News:HCA Reports Third Quarter 2007 Results 10Health News:HCA Reports Third Quarter 2007 Results 11Health News:HCA Reports Third Quarter 2007 Results 12Health News:HCA Reports Third Quarter 2007 Results 13Health News:HCA Reports Third Quarter 2007 Results 14Health News:RediClinic Announces Management Changes 2Health News:RediClinic Announces Management Changes 3Health News:Diabetes America Physicians Achieve Industry Recognition for Quality Patient Care 2Health News:AMDL Launches Expanded Distribution With 4th Round of Agreements Valued at $6.79 Million Annually for New Health & Beauty Product Line 2Health News:MannKind Corporation Reports Third Quarter Financial Results 2Health News:MannKind Corporation Reports Third Quarter Financial Results 3Health News:MannKind Corporation Reports Third Quarter Financial Results 4Health News:MannKind Corporation Reports Third Quarter Financial Results 5Health News:MannKind Corporation Reports Third Quarter Financial Results 6Health News:Insulet Corporation Announces Pricing of Secondary Public Offering 2
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... HealthWarehouse.com , Inc. (OTC: HEWA), a leading ... its pre-order program to enable consumers immediate access to Atorvastatin ... offer the medication at up to 50 percent less ... "We will be one of the earliest and ...
... Nov. 29, 2011  In a new study presented today at ... (RSNA), growth hormone replacement for six months was found to ... is the first time that the effects of growth hormone ... lead author, Miriam A. Bredella, M.D., a radiologist at Massachusetts ...
Cached Medicine Technology:HealthWarehouse.com Offers Lowest Price Generic Lipitor on the Market 2HealthWarehouse.com Offers Lowest Price Generic Lipitor on the Market 3Growth Hormone Increases Bone Formation in Obese Women 2
Tips are sharp on both sides to puncture, cut and tear the capsule...
...
...
... StressVue puts leading-edge stress testing within ... office or clinic to the most advanced ... vivid flat panel monitor with options for ... thermal printer for continuous printing. StressVue is ...
Medicine Products: